How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

535 results for

Third Generation Progestin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Gestodene + ethinylestradiol (Apleek). No place for a patch containing a third-generation progestin

Gestodene + ethinylestradiol (Apleek). No place for a patch containing a third-generation progestin Prescrire IN ENGLISH - Spotlight ''In the January issue of Prescrire International: gestodene + ethinylestradiol (Apleek°). No place for a patch containing a third-generation progestin'', 1 January 2016 {1} {1} {1} | | > > > In the January issue of Prescrire International: gestodene + ethinylestradiol (Apleek°). No place for a patch containing a third-generation progestin Spotlight Every month (...) , the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the January issue of Prescrire International: gestodene + ethinylestradiol (Apleek°). No place for a patch containing a third-generation progestin FREE DOWNLOAD Delivering the gestodene and ethinylestradiol combination via fancy transparent patches in no way avoids exposing women to the higher thrombotic risk associated with third

2016 Prescrire

2. Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins. (PubMed)

Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins. Although oral contraceptives (OCs) are the most common treatment in women with polycystic ovary syndrome (PCOS), their effects and safety on the metabolic profiles of these patients are relatively unknown. In this meta-analysis the effects of the different durations (from 3months to 1year) of OC treatment (...) using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed.PubMed, Scopus, Google Scholar and ScienceDirect databases (2001-2015) were searched to identify clinical trials investigating the effects of OC containing CA or third generation progestins on metabolic profiles of women with PCOS. Both fixed and random effect models were used. Subgroup analyses were performed based on the progestin compounds used and on duration of treatment.Oral

2017 Metabolism: clinical and experimental

3. Third Generation Progestin

Third Generation Progestin Third Generation Progestin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Third Generation Progestin Third (...) Generation Progestin Aka: Third Generation Progestin , Norgestrel , Levonorgestrel II. Class 19 Nor-Testosterone : Gonane III. Preparation: dl-Norgestrel Relative : 2.6 : 0 : 4.2 : 2.6 Anti- : Active Anabolic: Active Preparations (0.3/30) Ovral (0.5/50) ( ) (0.075) IV. Preparation: Levonorgestrel Relative : 5.3 : 0 : 8.3 : 5.1 Anti- : Active Anabolic: Active Preparations with (0.1/20) (0.15/30) (0.15/30) (0.15/30) (0.05/30 - 0.075/40 - 0.125/30) (0.15/30) - seasonal (0.09/20) - continuous V. Adverse

2018 FP Notebook

4. Estrogen-progestins and progestins for the management of endometriosis. (PubMed)

and progestins have safety/tolerability/cost profiles that allow long-term use. These compounds induce atrophy of eutopic and ectopic endometrium, have antiinflammatory and proapoptotic properties, and can be delivered via different modalities, including oral, transdermal, subcutaneous, intramuscular, vaginal, and intrauterine routes. At least two-thirds of symptomatic women are relieved from pain and achieve appreciable improvements in health-related quality of life. Progesterone resistance may cause (...) nonresponse in the remaining one-third. When using estrogen-progestins continuously, individualized, tailored cycling should be explained to improve compliance. All combinations demonstrated a similar effect on dysmenorrhea, independently from progestin type. Estrogen-progestins with the lowest possible estrogen dose should be chosen to combine optimal lesion suppression and thrombotic risk limitation. Progestins should be suggested in women who do not respond or manifest intolerance to estrogen

2016 Fertility and Sterility

5. Third Generation Progestin

Third Generation Progestin Third Generation Progestin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Third Generation Progestin Third (...) Generation Progestin Aka: Third Generation Progestin , Norgestrel , Levonorgestrel II. Class 19 Nor-Testosterone : Gonane III. Preparation: dl-Norgestrel Relative : 2.6 : 0 : 4.2 : 2.6 Anti- : Active Anabolic: Active Preparations (0.3/30) Ovral (0.5/50) ( ) (0.075) IV. Preparation: Levonorgestrel Relative : 5.3 : 0 : 8.3 : 5.1 Anti- : Active Anabolic: Active Preparations with (0.1/20) (0.15/30) (0.15/30) (0.15/30) (0.05/30 - 0.075/40 - 0.125/30) (0.15/30) - seasonal (0.09/20) - continuous V. Adverse

2015 FP Notebook

6. Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy (PubMed)

for transrepression, while the selected progestins from the second and third generation are efficacious AR agonists for transrepression. Considering the progestin potencies and their reported free serum concentrations relative to dihydrotestosterone and estradiol, our results suggest that the progestins are likely to exert AR-, but not ERα- or ERβ-mediated effects in vivo.Copyright © 2017 Elsevier Inc. All rights reserved. (...) and efficacies of selected progestins from different generations determined in parallel. We show that the progestins bind to the androgen receptor (AR) with similar affinities to each other and progesterone, while none bind estrogen receptor (ER)-β, and only norethisterone acetate, levonorgestrel and gestodene bind ERα. Comparative dose-response analysis revealed that progestins from the first three generations display similar androgenic activity to the natural androgen dihydrotestosterone

Full Text available with Trip Pro

2017 Biochemical and biophysical research communications

7. Progestins or GnRH antagonists for pituitary suppression during ovarian stimulation for assisted reproductive technology cycles

Progestins or GnRH antagonists for pituitary suppression during ovarian stimulation for assisted reproductive technology cycles Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne (...) and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6

2019 PROSPERO

8. The Effect of Different Types of Progestin on Sleeping of Menopausal Women

The Effect of Different Types of Progestin on Sleeping of Menopausal Women The Effect of Different Types of Progestin on Sleeping of Menopausal Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . The Effect of Different Types of Progestin on Sleeping of Menopausal Women The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02086032 Recruitment Status : Completed First Posted : March 13, 2014 Last Update Posted : May 31, 2017 Sponsor: Chiang Mai University Information provided by (Responsible Party

2014 Clinical Trials

9. General practice management of type 2 diabetes 2014-15

General practice management of type 2 diabetes 2014-15 Healthy Profession. Healthy Australia. www.racgp.org.au General practice management of type 2 diabetes 2014–15General practice management of type 2 diabetes – 2014–15 Disclaimer The information set out in this publication is current at the date of first publication and is intended for use as a guide of a general nature only and may or may not be relevant to particular patients or circumstances. Nor is this publication exhaustive (...) to health professionals possessing appropriate qualifications and skills in ascertaining and discharging their professional (including legal) duties, it is not to be regarded as clinical advice and, in particular, is no substitute for a full examination and consideration of medical history in reaching a diagnosis and treatment based on accepted clinical practices. Accordingly, The Royal Australian College of General Practitioners and Diabetes Australia and their respective employees and agents have

2014 Clinical Practice Guidelines Portal

10. Contraception: second-generation pill rather than the contraceptive patch or vaginal ring

or desogestrel (known as third-generation pills). Likewise, drospirenone, a progestin present in fourth-generation pills, exposes women to an increased risk of both venous thrombosis and arterial thrombosis (myocardial infarction and stroke). Compared with second- and third-generation pills, the risk of venous thrombosis is also increased with contraceptive skin patches and vaginal rings. Whether these methods increase the risk of arterial thrombosis is uncertain. In practice, when combined oestrogen (...) Contraception: second-generation pill rather than the contraceptive patch or vaginal ring Prescrire IN ENGLISH - Spotlight ''Contraception: second-generation pill rather than the contraceptive patch or vaginal ring '', 1 November 2013 {1} {1} {1} | | > > > Contraception: second-generation pill rather than the contraceptive patch or vaginal ring Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   | 

2013 Prescrire

11. Effects of combined oral contraceptives containing different progestins on plasma lipids and metabolic variables in reproductive-age women: a systematic review and meta-analysis

Effects of combined oral contraceptives containing different progestins on plasma lipids and metabolic variables in reproductive-age women: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email (...) , namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control

2017 PROSPERO

12. Progestin-only hormonal contraception and depression: a systematic review

Progestin-only hormonal contraception and depression: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect (...) articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text

2017 PROSPERO

13. Muscle maintenance after menopause: investigating estrogen and estrogen-progestin hormone replacement therapy use in postmenopausal women and measures of muscle mass

Muscle maintenance after menopause: investigating estrogen and estrogen-progestin hormone replacement therapy use in postmenopausal women and measures of muscle mass Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g (...) initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5

2016 PROSPERO

14. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare". (PubMed)

Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare". This study investigated whether gestodene-containing oral contraceptives (OCs) carry a higher risk of venous thromboembolism (VTE) than OCs containing progestins other than desogestrel and gestodene. The study was conducted based on the hypothesis that the biases and confounding factors that were present initially after the introduction of new so-called (...) in the user populations of so-called "third-generation" OCs (containing desogestrel and gestodene) and "second-generation" OCs (containing progestins other than desogestrel and gestodene) that were present shortly after market introduction of gestodene-containing OCs and that (ii) these differences seem to have disappeared over time.

2010 Contraception

15. Guidelines on Chronic Coronary Syndromes

test 18 3.1.5.6 Invasive testing 19 3.1.6 Step 6: assess event risk 21 3.1.6.1 Definition of levels of risk 22 3.2 Lifestyle management 23 3.2.1 General management of patients with coronary artery disease 23 3.2.2 Lifestyle modification and control of risk factors 23 3.2.2.1 Smoking 23 3.2.2.2 Diet and alcohol 24 3.2.2.3 Weight management 24 3.2.2.4 Physical activity 24 3.2.2.5 Cardiac rehabilitation 24 3.2.2.6 Psychosocial factors 24 3.2.2.7 Environmental factors 25 3.2.2.8 Sexual activity 25 (...) 3.2.2.9 Adherence and sustainability 25 3.2.2.10 Influenza vaccination 25 3.3 Pharmacological management 26 3.3.1 Anti-ischaemic drugs 26 3.3.1.1 General strategy 26 3.3.1.2 Available drugs 26 3.3.1.3 Patients with low blood pressure 29 3.3.1.4 Patients with low heart rate 29 3.3.2 Event prevention 30 3.3.2.1 Antiplatelet drugs 30 3.3.2.2 Anticoagulant drugs in sinus rhythm 30 3.3.2.3 Anticoagulant drugs in atrial fibrillation 31 3.3.2.4 Proton pump inhibitors 31 3.3.2.5 Cardiac surgery

Full Text available with Trip Pro

2019 European Society of Cardiology

16. Management of Dyslipidaemias

assessed on the level of TC and systolic BP before treatment, if known. The longer the treatment and the more effective it is, the greater the reduction in risk, but in general it will not be more than about one-third of the baseline risk. For example (...) in men (490 000 vs. 193 000). Prevention is defined as a co-ordinated set of actions, either at the population or individual level, aimed at eliminating or minimizing the impact of CV diseases and their related disabilities. More patients are surviving their first CVD event and are at high-risk of recurrences. In addition, the prevalence of some risk factors, notably diabetes (DM) and obesity, is increasing. The importance of ASCVD prevention remains undisputed and should be delivered at the general

Full Text available with Trip Pro

2019 European Society of Cardiology

17. Risk Factors for Endometrial Cancer - A review of the evidence

17 3 3.1 General factors 17 3.1.1 Age 17 3.2 Family history & genetics 19 3.2.1 Family history of endometrial cancer or colorectal cancer 19 3.2.2 Mismatch repair gene mutations 21 3.2.3 PTEN gene mutation 24 3.3 Endogenous hormones 26 3.3.1 Age at menarche 26 3.3.2 Age at menopause 27 3.3.3 Breastfeeding 28 3.3.4 Parity 30 3.3.5 Polycystic ovary syndrome (PCOS) 31 3.4 Exogenous Hormones 33 3.4.1 Hormonal contraception ?oral contraceptives 33 3.4.2 Hormonal infertility treatment 35 3.4.3 (...) Uterine cancer survival in Australia has improved over time. Between 1986–1990 and 2011– 2015, 5–year survival for women with uterine cancer increased from 77% to 83% compared to women in the general Australian population. 2 There is a general lack of awareness among the Australian community of the modifiable risk factors for developing endometrial cancer, and there is a lack of current research to summarise the available evidence on risk factors for endometrial cancer in the Australian context. 4, 5

2019 Cancer Australia

18. Diagnosis and management of epilepsy in adults

. It does not include patients with a non-epileptic attack disorder (see section 3.3.1). 1.2.2 TARGET USERS OF THE GUIDELINE This guideline will be of interest to all health professionals in primary and secondary care involved in the management of people with epilepsy, including general practitioners, practice nurses, epilepsy specialist nurses, general physicians, emergency department specialists, neurologists, obstetricians, clinical neuropsychologists and psychiatrists. It will also be of interest (...) (MA) also known as product licence. This is known as ‘off-label’ use. Medicines may be prescribed off label in the following circumstances: y for an indication not specified within the marketing authorisation y for administration via a different route y for administration of a different dose y for a different patient population. An unlicensed medicine is a medicine which does not have MA for medicinal use in humans. Generally off-label prescribing of medicines becomes necessary if the clinical

2018 SIGN

19. Heart Disease and Stroke Statistics

–0.92) mortality than those treated at noncertified hospitals, after adjustment for demographic and clinical factors. Hospitals certified between 2009 and 2013 also had lower in-hospital and 30-day mortality than centers certified before 2009. Congenital Cardiovascular Defects and Kawasaki Disease (Chapter 15) Although estimates of birth prevalence/overall prevalence of congenital cardiovascular defects appear relatively stable, a general trend toward improved outcome/survival continues, which has (...) led to an expanding population of adult congenital heart disease patients. Although there remains increased mortality in patients with congenital cardiovascular defects compared with the general population, the standardized mortality ratios after congenital heart disease surgery continue to decrease. In a recent study from the Pediatric Cardiac Care Consortium’s US-based multicenter data registry, which examined 35 998 patients with a median follow-up of 18 years, the overall standardized

Full Text available with Trip Pro

2019 American Heart Association

20. International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS)

and general preference for lower dose preparations. Metformin is recommended in addition or alone, primarily for metabolic features. Letrozole is first-line pharmacological infertility therapy; with clomiphene and metformin having a role alone and in combination. In women with PCOS and anovulatory infertility, gonadotrophins are second line. In the absence of an absolute indication for IVF, women with PCOS and anovulatory infertility, could be offered IVF third line where other ovulation induction (...) , developed the evidence-based guideline to provide evidence-based recommendations to improve the quality of healthcare, health outcomes and quality of life of women with PCOS. The guideline represents the integration of the best evidence available at the time of preparation, multidisciplinary, international clinical perspectives and patient preferences. In the absence of scientific evidence in PCOS, evidence from the general population was considered and a consensus between the engaged stakeholders

2018 European Society of Human Reproduction and Embryology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>